|1.||Esumi, Hiroyasu: 4 articles (01/2006 - 10/2004)|
|2.||López-Barneo, José: 3 articles (03/2012 - 06/2003)|
|3.||Maxwell, Patrick H: 3 articles (01/2011 - 01/2008)|
|4.||Caniggia, Isabella: 3 articles (09/2010 - 01/2007)|
|5.||Minchenko, Dmytro O: 3 articles (01/2006 - 01/2005)|
|6.||Opentanova, Iryna L: 3 articles (01/2006 - 01/2005)|
|7.||Minchenko, Oleksandr H: 3 articles (01/2006 - 01/2005)|
|8.||Ogura, Tsutomu: 3 articles (12/2005 - 10/2004)|
|9.||Cummins, Eoin P: 2 articles (11/2015 - 01/2008)|
|10.||Taylor, Cormac T: 2 articles (11/2015 - 01/2008)|
11/01/2014 - "Cells were subsequently treated with the hypoxia inducible factor (HIF)-activating compound, dimethyloxalylglycine (DMOG), to determine whether hypoxia-induced mitochondrial changes were HIF dependent or independent, and to assess the suitability of this cultured cardiac cell line for cardiovascular pharmacological studies. "
01/01/2014 - "In this study, we confirmed the effect of dimethyloxalylglycine (DMOG), a hypoxia-mimicking agent, on the HIF-1α signaling pathway and investigated the effect of DMOG on MSC osteogenic differentiation and the Wnt/β-catenin signaling pathway. "
08/01/2011 - "The goal of this study was to evaluate in vitro and in vivo the effects of up-regulation of the proangiogenic hypoxia inducible factor (HIF)-1α induced by dimethyloxalylglycine on endothelial cell cultures and on skin flap survival. "
11/01/2013 - "A first group (N = 6) of animals was treated with dimethyloxalylglycine, a drug known to stabilize hypoxia-inducible-factor-α, which among other functions, is involved in angiogenesis. "
04/01/2013 - "Hypoxia responses were triggered by pre-incubation in low O(2) or with the 2-oxoglutarate-dependent dioxygenase inhibitor dimethyloxalylglycine (DMOG). "
01/01/2013 - "Systemic administration of the HIF-1α stabilizer dimethyloxalylglycine (DMOG) resulted in enhanced expression of HIF-1α and improved nephrogenesis: kidneys from hyperoxia-exposed pups treated with DMOG exhibited a nephrogenic zone width and glomerular diameter similar to room-air controls. "
11/10/2015 - "Previous studies have shown that systemic (intraperitoneal) administration of hydroxylase inhibitors such as dimethyloxalylglycine (DMOG) is profoundly protective in multiple models of colitis, however the therapeutic potential of this approach is limited due to potential side-effects associated with systemic drug exposure and the fact that orally delivered DMOG is ineffective (likely due to drug inactivation by gastric acid). "
01/01/2008 - "The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis."
10/01/2011 - "A second experiment was performed to investigate whether FDG-μPET was able to detect differences in inflammation between two DSS-treated groups, one receiving placebo (n = 4) and one receiving dimethyloxalylglycine (DMOG) (n = 4), a compound that protects against DSS-induced colitis. "
01/01/2008 - "In this study we have investigated the effects of the hydroxylase inhibitor dimethyloxalylglycine (DMOG) on Caco-2 intestinal epithelial cells in vitro and in a dextran sodium sulfate-induced model of murine colitis. "
|5.||Wounds and Injuries (Trauma)
|1.||Procollagen-Proline Dioxygenase (Prolyl Hydroxylase)
|3.||Ethanol (Ethyl Alcohol)
|8.||Messenger RNA (mRNA)
|9.||Proteins (Proteins, Gene)
|10.||Succinic Acid (Succinate)
|1.||Transplantation (Transplant Recipients)